Status:
COMPLETED
Effects of Celecoxib After Percutaneous Coronary Intervention
Lead Sponsor:
Seoul National University Hospital
Conditions:
Coronary Arteriosclerosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce...
Eligibility Criteria
Inclusion
- Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography
Exclusion
- Acute ST elevation MI
- Left main disease
- Contraindications to aspirin, clopidogrel or celecoxib
- Severe congestive heart failure
- Expected survival \< 2 years
- Hepatic dysfunction
- Currently taking NSAIDs or any COX-2 inhibitor
- Renal dysfunction
- Use of warfarin
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00292721
Start Date
August 1 2004
End Date
October 1 2008
Last Update
July 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744